ANEXSIA 7.5/325 Drug Patent Profile

When do Anexsia 7.5/325 patents expire, and when can generic versions of Anexsia 7.5/325 launch?

Anexsia 7.5/325 is a drug marketed by Specgx Llc and is included in one NDA.

The generic ingredient in ANEXSIA 7.5/325 is acetaminophen; hydrocodone bitartrate. There is one drug master file entry for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the acetaminophen; hydrocodone bitartrate profile page.

Summary for ANEXSIA 7.5/325

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
DailyMed Link:	ANEXSIA 7.5/325 at DailyMed

Pharmacology for ANEXSIA 7.5/325

Drug Class	Opioid Agonist
Mechanism of Action	Opioid Agonists

US Patents and Regulatory Information for ANEXSIA 7.5/325

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Specgx Llc	ANEXSIA 7.5/325	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	040405-001	Sep 8, 2000	AA	RX	No	Yes

ANEXSIA 7.5/325 market dynamics and financial trajectory (acetaminophen + oxycodone) in key geographies

ANEXSIA 7.5/325 is a fixed-dose combination of oxycodone (7.5 mg) and acetaminophen (325 mg), sold as an oral immediate-release analgesic. Public financials are limited because the product is positioned as a branded combo and is typically reported under company-level or distributor-level line items rather than standalone drug P&Ls. The product’s commercial trajectory is driven by (1) opioid supply and prescribing constraints, (2) competitive substitution by other oxycodone/acetaminophen strengths and extended-release opioids, (3) formulary access and prior authorization behavior, and (4) patent/brand-life conversion risk if exclusivity lapses in the relevant market.

---

What is ANEXSIA 7.5/325 and how is it positioned in pain management?

ANEXSIA 7.5/325 is an opioid-based combination product for moderate pain. In most markets, oxycodone/acetaminophen brands compete in the same therapeutic bucket as immediate-release oxycodone combinations, tramadol combinations, and alternative opioid agonists depending on payer preference and national opioid stewardship policies.

Which active ingredients and dose format matter commercially

• Actives: oxycodone hydrochloride (7.5 mg) + acetaminophen (325 mg)
• Dosage form: oral immediate-release tablet (typical for oxycodone/acetaminophen combo brands at this strength)
• Clinical role: short-term or episodic moderate pain management; titration is constrained by combination dosing (fixed acetaminophen ceiling)

What payers typically demand

• Step edits or prior authorization for opioid initiation in many formularies
• Limits on daily morphine milligram equivalents (MME) or opioid-days supply
• Toxicity and liver-risk messaging for acetaminophen exposure

---

How do opioid prescribing controls and safety policy shape demand for ANEXSIA 7.5/325?

Opioid market demand is not governed only by patient need; it is governed by prescribing behavior and compliance infrastructure. For an oxycodone/acetaminophen brand, the key effect is volume compression through payer rules and prescriber risk management.

Market levers that directly affect sales

1. Limits on opioid days supply
   • Fewer refills per prescription for opioid combinations reduces repeat purchasing velocity.
2. Prior authorization and formulary tightening
   • Brands lose share when a “preferred” oxycodone combination or a generic is on the preferred tier.
3. Prescriber and pharmacy monitoring
   • Risk mitigation programs increase friction for opioid dispensing, raising abandonment rates at the margin.
4. Acetaminophen maximum daily dosing scrutiny
   • Fixed-dose products can trigger prescriber substitution toward different formulations when comorbidity or polypharmacy increases acetaminophen risk.

Competitive substitution pressure

• Many formularies steer toward generic immediate-release oxycodone/acetaminophen or different opioid classes (for example, hydrocodone combinations or tramadol where permitted).
• When prescribers face “lowest acquisition cost” incentives, brands with no insurer rebates or weak formulary standing typically see faster erosion.

Bottom line: opioid stewardship trends act like a structural demand drag. For a mid-strength combination, the product usually survives via contracts and access, not via category growth.

---

What market dynamics determine whether ANEXSIA 7.5/325 gains or loses share?

ANEXSIA’s share trajectory depends on three commercial mechanics: access (coverage), conversion (where doctors prescribe from), and substitution (what replaces it when patients switch).

Access mechanics

• Tier placement (preferred vs non-preferred)
• Coverage breadth (commercial vs managed Medicaid vs government)
• Prior authorization criteria (opioid-naïve patients vs established therapy)

Conversion mechanics

• Dose switching within the oxycodone/acetaminophen family
• “Tablet count economics” (patients want fewer tablets when titrating; payers may favor standard pack sizes)
• Prescriber familiarity with specific brands

Substitution mechanics

• Same-class substitution: other oxycodone/acetaminophen strengths or alternative immediate-release brands
• Generic substitution: entry of authorized generics or standard generics typically drives price erosion
• Class substitution: extended-release opioid strategies for persistent pain (if covered)

Bottom line: most fixed-dose opioid combination brands track the formulary access curve more closely than they track underlying pain prevalence.

---

When does ANEXSIA 7.5/325 lose exclusivity, and what generic entry risks exist?

No reliable, complete exclusivity timeline can be produced from the information provided. A fixed-dose combination of oxycodone and acetaminophen is commonly subject to early generic conversion because the actives have long histories in multiple jurisdictions. Without Orange Book-style listing data tied specifically to ANEXSIA 7.5/325 in the relevant country, an exclusivity and filing-date-based generic risk assessment cannot be stated accurately.

Commercial risk framework that typically applies to products like this (directional, not a date call):

Last updated: July 18, 2026

• If the product is no longer protected by brand-specific composition, method-of-use, or formulation IP in a given jurisdiction, generic entry drives rapid revenue compression.
• If patent or regulatory exclusivities remain, revenue can hold longer through 180-day exclusivity windows for first filers, but only if a challenge strategy is in place and granted.

Because this analysis requires country-specific regulatory and patent data to be accurate, no hard launch timing is provided.

---

What is the Orange Book status of ANEXSIA 7.5/325 (and does it list patents that block generics)?

Orange Book status cannot be determined from the provided input. Without a verified U.S. listing record for ANEXSIA 7.5/325 (product code and strength) the patent listing status, exclusivity blocks, and Paragraph IV pathway cannot be confirmed.

---

What patent estate protects ANEXSIA 7.5/325, and how strong is it?

A strength assessment requires:

• A mapped patent set for the exact combination and dosage form
• Expiration dates by jurisdiction
• Whether the listed patents are formulation, process, method-of-use, or packaging
• Litigation/claims status

No such patent estate data is provided in the prompt, so the protected landscape cannot be stated.

---

What formulation and manufacturing/IP barriers affect generic competition for oxycodone/acetaminophen brands like ANEXSIA?

Even when regulatory pathways are open, manufacturing and IP can affect generic speed. For oxycodone/acetaminophen tablets, barriers typically come from:

• Bioequivalence formulation constraints (immediate-release release profile)
• Process controls (granulation, compression, dissolution)
• Any brand-specific improvements that could trigger patent disputes

However, the actual barriers for ANEXSIA 7.5/325 depend on that product’s specific formulation and patent filings. Without those details, a barrier inventory cannot be produced.

---

Which companies compete with ANEXSIA 7.5/325 in the same pain segment?

Competitive sets for oxycodone/acetaminophen brands usually include:

• Other immediate-release oxycodone/acetaminophen combination products at comparable strengths
• Generic equivalents if available and preferred
• Alternative opioid combinations (commonly hydrocodone/acetaminophen)
• In some systems, tramadol combinations or non-opioid adjuvants depending on guidelines

A precise competitor list for ANEXSIA 7.5/325 requires market-specific assortment and formulary data, which is not included.

---

How do pricing and reimbursement dynamics translate into ANEXSIA 7.5/325 revenue trajectory?

For opioid combination tablets, revenue typically follows a predictable pattern once:

• generics enter,
• PBM preferred-tier rules change, or
• public health enforcement changes prescribing behavior.

Revenue levers that typically dominate

• Net price vs gross list price
  • Rebates and contract terms determine realized revenue; net-to-gross compression is common when access weakens.
• Volume elasticity under prior authorization
  • Restrictive rules reduce prescriptions and refill rates.
• Dispensing substitution
  • Pharmacies select the covered SKU with the lowest cost sharing.

What to expect commercially

• Early-stage brands: growth driven by detailing and formulary placements.
• Mid/late-stage: volume stabilizes or declines as generic competition and opioid policies tighten.
• Late-stage: revenue collapses faster than unit demand if net pricing declines quickly.

Because the prompt does not specify country, distributor channel, or historical unit and revenue metrics, no quantified financial trajectory can be stated.

---

What litigation risk affects oxycodone/acetaminophen commercial outlook for ANEXSIA?

Oxycodone/acetaminophen products operate in an environment shaped by opioid-related litigation and settlements that influence:

• corporate risk costs,
• market access priorities,
• and sometimes supply and promotion practices.

To tie litigation directly to ANEXSIA 7.5/325, the brand’s manufacturer/labeler and jurisdiction must be identified, and settlement impacts must be mapped to that specific label entity. None of that is included.

---

Is ANEXSIA 7.5/325 affected by biologic/biosimilar dynamics?

No. ANEXSIA 7.5/325 is a small-molecule opioid/analgesic combination. Biosimilar dynamics are not applicable.

---

Key takeaways

• ANEXSIA 7.5/325 is an oxycodone/acetaminophen immediate-release combination, competing in a category governed by opioid stewardship and payer access controls.
• Market dynamics for this product are driven by formulary tiering, prior authorization friction, substitution to other oxycodone combinations or generics, and acetaminophen exposure risk considerations.
• A date-specific exclusivity and generic-entry risk assessment, Orange Book/patent estate mapping, and litigation impact linkage cannot be produced from the provided input because the required regulatory and patent records are not specified.
• Financial trajectory, if modeled, would typically show demand compression from opioid policy and faster revenue erosion after generic access improves, with net price compression often the dominant driver.

---

FAQs

1. How do PBM prior authorization rules change oxycodone/acetaminophen brand sales momentum?
   They reduce opioid-naïve starts and raise refill friction, shrinking prescription and repeat purchase velocity.

2. What dosing constraints make fixed oxycodone/acetaminophen combinations easier or harder to substitute?
   Fixed acetaminophen limits and fixed opioid dose can push prescribers to different strengths or different opioid classes.

3. When generic oxycodone/acetaminophen tablets enter, what happens to net revenue versus unit volume?
   Net revenue typically falls faster than unit volume because rebate pressure and tier migration drive steep net price compression.

4. Do opioid settlements or enforcement actions materially alter distribution and purchasing behavior for brands?
   They can, via corporate risk posture and tighter market access practices, affecting formulary positioning and promotion.

5. What manufacturing variables most influence generic adoption for immediate-release opioid/acetaminophen tablets?
   Dissolution and release profile matching, plus process consistency affecting bioequivalence, are central.

---

References (APA)

1. No sources cited.